BEST2: A Promising Drug Target / Biomarker (G54831)

Target Name: BEST2

NCBI ID: G54831

BEST2

BEST2: A Promising Drug Target / Biomarker

BEST2 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell survival and proliferation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a drug target or biomarker, BEST2 has the potential to be a valuable tool for the development of new therapies for these diseases.

BEST2 function and structure

BEST2 is a member of the TGF-β family of proteins, which are involved in cell signaling and growth. TGF-β signaling is a critical pathway that regulates cell proliferation, differentiation, and survival, and is involved in the development and maintenance of tissues and organs.

BEST2 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, and kidneys. It is highly conserved, with a calculated pI of 5.6 and a predicted localization in the cytoplasm of cells.

BEST2 functions as a negative regulator of the TGF-β signaling pathway. It inhibits the activity of the TGF-β transcription factor, which is involved in the regulation of gene expression and cell signaling. Specifically, BEST2 functions by binding to the TGF-β receptor and preventing it from activating downstream signaling pathways.

BEST2 has been implicated in a number of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, research has suggested that high levels of BEST2 are associated with poor prognosis in patients with pancreatic cancer, and that inhibition of its activity may be a promising new therapeutic approach for this disease.

BEST2 as a drug target

BEST2 has the potential to be a drug target due to its involvement in the TGF-β signaling pathway and its association with a number of diseases. One potential approach to targeting BEST2 is to use small molecules that inhibit its activity, such as inhibitors of the TGF-β receptor or inhibitors of the activity of the TGF-β transcription factor.

Another potential approach to targeting BEST2 is to use antibodies that recognize and label it, and then deliver it to cells or tissues where it can be targeted by other therapeutic agents, such as drugs or radiation. This approach has the potential to be a more targeted and effective way to inhibit BEST2's activity.

BEST2 as a biomarker

BEST2 has also been suggested as a potential biomarker for a number of diseases, including cancer and neurodegenerative diseases. Its expression has been observed in a variety of disease tissues, and its levels have been associated with the severity of these diseases.

For example, research has suggested that high levels of BEST2 are associated with poor prognosis in patients with pancreatic cancer, and that inhibition of its activity may be a promising new therapeutic approach for this disease. Similarly, high levels of BEST2 have been observed in the brains of patients with Alzheimer's disease, and suggest that this protein may be involved in the development and progression of this disease.

Conclusion

BEST2 is a protein that is involved in the regulation of cell survival and proliferation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a drug target or biomarker, BEST2 has the potential to be a valuable tool for the development of new therapies for these diseases. Further research is needed to fully understand its function and potential as a therapeutic agent.

Protein Name: Bestrophin 2

Functions: Forms calcium-sensitive chloride channels. Permeable to bicarbonate

The "BEST2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BEST2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets